Aloesone
Based on 1 Customer Validation
Aloesone is an orally active phenolic heptaketide natural product that can cross the blood-brain barrier. Aloesone inhibits LPS-induced oxidative stress, inflammation, M1 polarization and apoptosis in RAW264.7 macrophages by reducing ROS production and NO release, and downregulating the mRNA expression of iNOS, IL-1β and TNF-α. Aloesone also inhibits glutamate-induced neuronal damage and pentylenetetrazol (PTZ)-induced seizures by activating c-SRC.
For research use only. We do not sell to patients.
- Purity : 99.49%
- CAS No.: 40738-40-7
- Formula: C13H12O4
- Molecular Weight:232.23
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[2]|
iNOS |
IL-1β |
In Vitro
Aloesone (0.1-1000 μM; 12 h) shows no cytotoxicity in RAW264.7 murine macrophages after 12 h of incubation[1].
Aloesone (0.1-1000 μM; 24 h) is non-toxic to murine hippocampal HT22 cells at concentrations up to 100 μM after 24 h incubation, with reduced viability observed only at 1000 μM[3].
Aloesone (0.1-100 μM; 12 h) activates c-SRC signaling in glutamate-stimulated murine hippocampal HT22 cells after 12 h co-incubation by increasing phosphorylation at Y418 and decreasing phosphorylation at Y529, without changing total c-SRC expression[3].
Aloesone (0.1-100 μM; 2 h pretreatment, followed by 12 h LPS exposure) dose-dependently inhibits LPS-induced oxidative stress in RAW264.7 murine macrophages by reducing ROS production and upregulating Gpx-1 and SOD-1 mRNA expression[1].
Aloesone (0.1-100 μM; 2 h pretreatment, followed by 12 h LPS exposure) inhibits LPS-induced inflammation in RAW264.7 murine macrophages by reducing NO release and downregulating iNOS, IL-1β, and TNF-α mRNA expression[1].
Aloesone (0.1-100 μM; 2 h pretreatment, followed by 12 h LPS exposure) inhibits LPS-induced M1 polarization in RAW264.7 murine macrophages by reducing CD86 surface expression and altering M1-specific cell morphology[1].
Aloesone (0.1-100 μM; 2 h pretreatment, followed by 12 h LPS exposure) dose-dependently inhibits LPS-induced early and late phase apoptosis in RAW264.7 murine macrophages[1].
Aloesone (0.1-100 μM; 12 h) reduces total apoptosis, and at 1 μM specifically reduces early-phase apoptosis, in glutamate-stimulated murine hippocampal HT22 cells after 12 h co-incubation[3].
Aloesone (0.1-100 μM; 2 h pretreatment, followed by 12 h LPS exposure) exerts protective effects in LPS-stimulated RAW264.7 murine macrophages by inhibiting the activation of mTOR, p-mTOR, and HIF-1α, and reducing membrane expression of TLR4[1].
Aloesone (1 μM; 24 h) reduces intracellular ROS levels in glutamate-stimulated murine hippocampal HT22 cells after 24 h co-incubation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:murine macrophage RAW264.7 cells
-
Concentration:0.1, 1, 10, 100, 1000 μM
-
Incubation Time:12 h
-
Result:Did not affect the survival rate of RAW264.7 cells.
-
Cell Line:LPS-stimulated murine macrophage RAW264.7 cells
-
Concentration:0.1, 1, 10, 100 μM
-
Incubation Time:2 h pretreatment
-
Result:Prevented LPS-induced early phase apoptosis in a dose-dependent manner.
Reduced LPS-induced late phase apoptosis.
-
Cell Line:LPS-stimulated murine macrophage RAW264.7 cells
-
Concentration:0.1, 1, 10, 100 μM
-
Incubation Time:2 h pretreatment
-
Result:Significantly repressed LPS-induced activation of mTOR, p-mTOR, and HIF-1α.
Decreased LPS-induced membrane expression of TLR4.
-
Cell Line:murine hippocampal HT22 cells
-
Concentration:0.1, 1, 10, 100, 1000 μM
-
Incubation Time:24 h
-
Result:Did not affect cell viability at 0.1, 1, 10, and 100 μM after 24 h.
Reduced cell viability at 1000 μM after 24 h.
-
Cell Line:glutamate-stimulated murine hippocampal HT22 cells
-
Concentration:0.1, 1, 10, 100 μM
-
Incubation Time:12 h
-
Result:Reduced chromatin condensation and nuclear shrinkage.
Decreased total apoptosis rate.
Reduced early-phase apoptosis at 1 μM, with no effect on late-phase apoptosis.
-
Cell Line:glutamate-stimulated murine hippocampal HT22 cells
-
Concentration:0.1, 1, 10, 100 μM
-
Incubation Time:12 h
-
Result:Increased fluorescence intensity of phosphorylated c-SRC at Y418.
Decreased fluorescence intensity of phosphorylated c-SRC at Y529.
Did not alter total c-SRC protein levels.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | AUC0-t | AUC0-∞ | T1/2 | MRT0-t | CLz | Vz | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[2] | 1.0 mg/kg | i.v. | 193.4 ng/mL | 0.083 h | 86.08 ng/mL·h | 94.78 ng/mL·h | 1.78 h | 0.71 h | 10.72 mL/h/kg | 26.42 L/kg | / |
| Rat[2] | 10 mg/kg | p.o. | 53.63 ng/mL | 0.083 h | 68.44 ng/mL·h | 119.35 ng/mL·h | 3.07 h | 1.59 h | 96.58 L/h/kg | 433.95 L/kg | 12.59 % |
In Vivo
Aloesone (50 mg/kg; p.o.; administered 30 min prior to each PTZ injection; for 26 consecutive days) suppresses PTZ-induced chronic seizures in rats by reducing seizure scores, prolonging seizure latency, and enhancing c-SRC activation via decreasing Y529 phosphorylation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 250 g, pentylenetetrazol-induced acute seizure model)[3]
-
Dosage:50, 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Prolonged the seizure latent period to 777.60 s, reduced seizure scores to 2.6, and increased survival rate to 80.0%.
Increased phosphorylation of c-SRC at Y418 and decreased phosphorylation at Y529 in the hippocampus.
Reduced seizure scores but did not significantly prolong latent period or improve survival rate, and increased phosphorylation of c-SRC at Y529.
-
Animal Model:Sprague-Dawley (male, 250 g, pentylenetetrazol-induced chronic seizure model)[3]
-
Dosage:50 mg/kg
-
Administration:p.o.; administered 30 minutes prior to each PTZ injection; 26 days
-
Result:Did not affect rat body weights over 26 days.
Reduced seizure scores and increased seizure latent period on days 19 and 21 compared to PTZ-only rats.
Decreased phosphorylation of c-SRC at Y529 in the hippocampus.
Chemical Information
-
CAS No. 40738-40-7
-
Appearance Solid
-
Molecular Weight 232.23
-
Formula C13H12O4
-
Color Off-white to light yellow
-
SMILES
O=C1C=C(CC(C)=O)OC2=CC(O)=CC(C)=C12
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (430.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang Y, et al. Multiple Beneficial Effects of Aloesone from on LPS-Induced RAW264.7 Cells, Including the Inhibition of Oxidative Stress, Inflammation, M1 Polarization, and Apoptosis. Molecules (Basel, Switzerland). 2023 Feb 08;28(4):1617. [Content Brief]
[4]. Reza Nazifi SM, et al. Antioxidant properties of Aloe vera components: a DFT theoretical evaluation. Free Radic Res. 2019 Aug;53(8):922-931. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3061 mL | 21.5304 mL | 43.0608 mL | 107.6519 mL |
| 5 mM | 0.8612 mL | 4.3061 mL | 8.6122 mL | 21.5304 mL | |
| 10 mM | 0.4306 mL | 2.1530 mL | 4.3061 mL | 10.7652 mL | |
| 15 mM | 0.2871 mL | 1.4354 mL | 2.8707 mL | 7.1768 mL | |
| 20 mM | 0.2153 mL | 1.0765 mL | 2.1530 mL | 5.3826 mL | |
| 25 mM | 0.1722 mL | 0.8612 mL | 1.7224 mL | 4.3061 mL | |
| 30 mM | 0.1435 mL | 0.7177 mL | 1.4354 mL | 3.5884 mL | |
| 40 mM | 0.1077 mL | 0.5383 mL | 1.0765 mL | 2.6913 mL | |
| 50 mM | 0.0861 mL | 0.4306 mL | 0.8612 mL | 2.1530 mL | |
| 60 mM | 0.0718 mL | 0.3588 mL | 0.7177 mL | 1.7942 mL | |
| 80 mM | 0.0538 mL | 0.2691 mL | 0.5383 mL | 1.3456 mL | |
| 100 mM | 0.0431 mL | 0.2153 mL | 0.4306 mL | 1.0765 mL |